Rabeprazole

Rabeprazole is a substituted benzimidazole proton-pump inhibitor supplied here as the free compound rather than its sodium salt. After acid-dependent activation, the active species inhibits gastric H+/K+-ATPase, suppressing the final step of gastric acid secretion. In pharmaceutical development, the free compound also provides the precursor from which rabeprazole sodium can be prepared.

The benzimidazole–sulfoxide–pyridine structure accounts for both its pharmacological function and its sensitivity to acidic conditions. Commercial oral rabeprazole products commonly use the sodium salt with delayed-release protection. Accordingly, this free-form material belongs upstream in salt preparation, solid-state investigation and formulation research; it should not be described as interchangeable by weight with rabeprazole sodium or as a finished oral medicine.

Typical Applications

• Rabeprazole sodium preparation: Used as the free-form precursor in pharmaceutical synthesis routes that introduce sodium and isolate the corresponding drug-substance salt for subsequent formulation.
• Delayed-release formulation development: Used in development studies involving conversion to the intended salt, protection of the acid-sensitive drug and measurement of release from enteric-protected oral dosage forms.
• Proton-pump inhibition research: Used in laboratory investigations of acid activation and gastric H+/K+-ATPase inhibition, connecting chemical stability and activation behavior with suppression of gastric acid secretion.

Specifications

Specifications describe the standard grade. Tolerance, test method and documentation package are confirmed per order.